Caleigh Propes
@caleighpropes.bsky.social
PhD Candidate in Bioethics & Health Policy at Johns Hopkins. Interested in FDA policy & research ethics. she/her
Reposted by Caleigh Propes
Viewpoint: Rapid advances in psychedelic research and policy have created a patchwork of laws regulating access, marketing, and payment, leading to confusion, potential safety issues, and disparities in treatment. ja.ma/3Xqcsfu
November 12, 2025 at 2:00 PM
Viewpoint: Rapid advances in psychedelic research and policy have created a patchwork of laws regulating access, marketing, and payment, leading to confusion, potential safety issues, and disparities in treatment. ja.ma/3Xqcsfu
Reposted by Caleigh Propes
New article published in
@jamahealthforum.com that examines and critiques 4 aspects of the current pathwork of regulations covering access to psychedelics––and then provides constructive, sensible, and actionable ways forward for each.
Work led by drug policy expert @caleighpropes.bsky.social
@jamahealthforum.com that examines and critiques 4 aspects of the current pathwork of regulations covering access to psychedelics––and then provides constructive, sensible, and actionable ways forward for each.
Work led by drug policy expert @caleighpropes.bsky.social
New today in JAMA Health Forum: Our team discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.
Gaps in US Psychedelic Policy and How to Close Them | Health Policy - By @caleighpropes.bsky.social, @katherinecheung.bsky.social, Matthew Eisenberg, David Yaden | @jama.com Health Forum jamanetwork.com/journals/jam...
November 10, 2025 at 3:37 PM
New article published in
@jamahealthforum.com that examines and critiques 4 aspects of the current pathwork of regulations covering access to psychedelics––and then provides constructive, sensible, and actionable ways forward for each.
Work led by drug policy expert @caleighpropes.bsky.social
@jamahealthforum.com that examines and critiques 4 aspects of the current pathwork of regulations covering access to psychedelics––and then provides constructive, sensible, and actionable ways forward for each.
Work led by drug policy expert @caleighpropes.bsky.social
New today in JAMA Health Forum: Our team discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.
Gaps in US Psychedelic Policy and How to Close Them | Health Policy - By @caleighpropes.bsky.social, @katherinecheung.bsky.social, Matthew Eisenberg, David Yaden | @jama.com Health Forum jamanetwork.com/journals/jam...
Gaps in US Psychedelic Policy and How to Close Them
This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration...
jamanetwork.com
November 7, 2025 at 9:36 PM
New today in JAMA Health Forum: Our team discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.
Reposted by Caleigh Propes
Gaps in US Psychedelic Policy and How to Close Them | Health Policy - By @caleighpropes.bsky.social, @katherinecheung.bsky.social, Matthew Eisenberg, David Yaden | @jama.com Health Forum jamanetwork.com/journals/jam...
Gaps in US Psychedelic Policy and How to Close Them
This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration...
jamanetwork.com
November 7, 2025 at 8:33 PM
Gaps in US Psychedelic Policy and How to Close Them | Health Policy - By @caleighpropes.bsky.social, @katherinecheung.bsky.social, Matthew Eisenberg, David Yaden | @jama.com Health Forum jamanetwork.com/journals/jam...
New paper thread 🧵 Out today in Annals of Internal Medicine, Stephanie Morain @bermaninstitute.bsky.social and I discuss the role of IRBs in facilitating appropriate inclusion of pregnant people in clinical research: www.acpjournals.org/doi/10.7326/... (1/6)
Overdue: Delayed Revision of Institutional Review Board Policies Characterizing Pregnant Women After the Revised Common Rule | Annals of Internal Medicine
www.acpjournals.org
November 3, 2025 at 11:47 PM
New paper thread 🧵 Out today in Annals of Internal Medicine, Stephanie Morain @bermaninstitute.bsky.social and I discuss the role of IRBs in facilitating appropriate inclusion of pregnant people in clinical research: www.acpjournals.org/doi/10.7326/... (1/6)
Reposted by Caleigh Propes
#ASBH25 - 3:45p PT | IRB Practices in Promoting Inclusion of Pregnant People in Research, Caleigh Propes | B119 asbh25.eventscribe.net/fsPopup.asp?...
2025 ASBH Annual Conference
asbh25.eventscribe.net
October 24, 2025 at 9:59 PM
#ASBH25 - 3:45p PT | IRB Practices in Promoting Inclusion of Pregnant People in Research, Caleigh Propes | B119 asbh25.eventscribe.net/fsPopup.asp?...
Reposted by Caleigh Propes
"Too often, [Ruth] Faden told me, pregnant women are still viewed as fragile vessels who need to be sequestered from the world. 'We need to protect women through research, not from research,' she said."
Why We Know So Little About Medicines During Pregnancy
Trump’s attacks on Tylenol come after decades in which many women were excluded from medical studies, which has created uncertainty about which drugs are safe.
www.newyorker.com
October 1, 2025 at 11:30 PM
"Too often, [Ruth] Faden told me, pregnant women are still viewed as fragile vessels who need to be sequestered from the world. 'We need to protect women through research, not from research,' she said."
Reposted by Caleigh Propes
Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis - Katherine Cheung, Caleigh Propes, Marianna Graziosi, Kyle Patch, David Yaden | AJOB Empirical Bioethics www.tandfonline.com/doi/full/10....
Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis
Classic psychedelics, such as psilocybin and LSD, evoke certain kinds of altered states of consciousness. Specific features of the experience, such as its allegedly ineffable nature, have been disc...
www.tandfonline.com
July 21, 2025 at 1:34 PM
Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis - Katherine Cheung, Caleigh Propes, Marianna Graziosi, Kyle Patch, David Yaden | AJOB Empirical Bioethics www.tandfonline.com/doi/full/10....
Reposted by Caleigh Propes
Ruth Faden & Nancy Kass - The abrupt end of USAID-funded clinical trials is profoundly unethical: It’s also dangerous to the health of thousands of trial participants www.statnews.com/2025/02/16/u... via @statnews.com
The abrupt end of USAID-funded clinical trials is profoundly unethical
USAID's stop-work order threatens to undo decades of progress in medical research ethics and cause harm to clinical trial participants.
www.statnews.com
February 16, 2025 at 1:16 PM
Ruth Faden & Nancy Kass - The abrupt end of USAID-funded clinical trials is profoundly unethical: It’s also dangerous to the health of thousands of trial participants www.statnews.com/2025/02/16/u... via @statnews.com
Reposted by Caleigh Propes
"We have come a long way in preventing disease through vaccination, and we must not lose our progress."
This Viewpoint discusses the importance of early and continued vaccine use in the US.
ja.ma/42FLxAn
#MedSky
This Viewpoint discusses the importance of early and continued vaccine use in the US.
ja.ma/42FLxAn
#MedSky
February 6, 2025 at 4:19 PM
"We have come a long way in preventing disease through vaccination, and we must not lose our progress."
This Viewpoint discusses the importance of early and continued vaccine use in the US.
ja.ma/42FLxAn
#MedSky
This Viewpoint discusses the importance of early and continued vaccine use in the US.
ja.ma/42FLxAn
#MedSky
Reposted by Caleigh Propes
Ethical considerations for sharing aggregate results from pragmatic clinical trials - Stephanie R Morain, Abigail Brickler, Joe Ali, Pearl O’Rourke, Kayte Spector-Bagdady, Benjamin Wilfond, Vasiliki Rahimzadeh, Caleigh Propes, Kayla Mehl, David Wendler journals.sagepub.com/doi/10.1177/...
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
November 26, 2024 at 4:04 PM
Ethical considerations for sharing aggregate results from pragmatic clinical trials - Stephanie R Morain, Abigail Brickler, Joe Ali, Pearl O’Rourke, Kayte Spector-Bagdady, Benjamin Wilfond, Vasiliki Rahimzadeh, Caleigh Propes, Kayla Mehl, David Wendler journals.sagepub.com/doi/10.1177/...
Reposted by Caleigh Propes
Untapped Potential? Representativeness in Pragmatic Clinical Trials | Research, Methods, Statistics - By Caleigh Propes, Kayla Mehl, & Stephanie R. Morain | JAMA jamanetwork.com/journals/jam...
Representativeness in Pragmatic Clinical Trials
This JAMA Viewpoint explores the potential of pragmatic clinical trials to improve demographic representativeness and health equity in clinical research.
jamanetwork.com
November 20, 2024 at 8:10 PM
Untapped Potential? Representativeness in Pragmatic Clinical Trials | Research, Methods, Statistics - By Caleigh Propes, Kayla Mehl, & Stephanie R. Morain | JAMA jamanetwork.com/journals/jam...
Reposted by Caleigh Propes
Recurring and Emerging Ethical Issues in Pragmatic Clinical Trials by Caleigh Propes, Pearl O'Rourke, Stephanie Morain | Circulation: Cardiovascular Quality and Outcomes www.ahajournals.org/doi/full/10....
American Heart Association Journals
www.ahajournals.org
July 19, 2024 at 5:01 PM
Recurring and Emerging Ethical Issues in Pragmatic Clinical Trials by Caleigh Propes, Pearl O'Rourke, Stephanie Morain | Circulation: Cardiovascular Quality and Outcomes www.ahajournals.org/doi/full/10....